{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:58:11Z","timestamp":1762102691769,"version":"3.44.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ejphar.2021.174659","type":"journal-article","created":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T01:41:14Z","timestamp":1638582074000},"page":"174659","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Characterisation of bis(4-aminoquinoline)s as \u03b11A adrenoceptor allosteric modulators"],"prefix":"10.1016","volume":"916","author":[{"given":"Junli","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3583-4246","authenticated-orcid":false,"given":"Adrian P.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence P.G.","family":"Wakelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4598-6745","authenticated-orcid":false,"given":"Angela M.","family":"Finch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2021.174659_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0014-2999(86)90202-5","article-title":"Differences between central and peripheral rat alpha-adrenoceptors revealed using binuclear ligands","volume":"127","author":"Adams","year":"1986","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174659_bib2","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0026-895X(25)12379-1","article-title":"Interaction of DNA-intercalating antitumor agents with adrenoceptors","volume":"27","author":"Adams","year":"1985","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174659_bib3","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1139\/o04-123","article-title":"Cardiac-specific transgenic overexpression of alpha1B-adrenergic receptors induce chronic activation of ERK MAPK signalling","volume":"82","author":"Benoit","year":"2004","journal-title":"Biochem. Cell. Biol."},{"key":"10.1016\/j.ejphar.2021.174659_bib4","doi-asserted-by":"crossref","first-page":"8299","DOI":"10.1021\/acs.jmedchem.8b00838","article-title":"6-Substituted hexamethylene amiloride (HMA) derivatives as potent and selective inhibitors of the human urokinase plasminogen activator for use in cancer","volume":"61","author":"Buckley","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2021.174659_bib5","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejphar.2014.03.034","article-title":"An aspartate in the second extracellular loop of the alpha(1B) adrenoceptor regulates agonist binding","volume":"733","author":"Campbell","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174659_bib6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1124\/mol.116.105874","article-title":"Homobivalent conjugation increases the allosteric effect of 9-aminoacridine at the alpha1-adrenergic receptors","volume":"91","author":"Campbell","year":"2017","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174659_bib7","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.yjmcc.2006.01.015","article-title":"Sustained augmentation of cardiac alpha1A-adrenergic drive results in pathological remodeling with contractile dysfunction, progressive fibrosis and reactivation of matricellular protein genes","volume":"40","author":"Chaulet","year":"2006","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.ejphar.2021.174659_bib8","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.1016\/j.bmc.2014.09.017","article-title":"Human alpha1-adrenoceptor subtype selectivity of substituted homobivalent 4-aminoquinolines","volume":"22","author":"Chen","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejphar.2021.174659_bib9","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.bcp.2013.03.010","article-title":"alpha(1)-Adrenoceptor and serotonin 5-HT(1A) receptor affinity of homobivalent 4-aminoquinoline compounds: an investigation of the effect of linker length","volume":"85","author":"Chen","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174659_bib10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature22309","article-title":"Structural insight into allosteric modulation of protease-activated receptor 2","volume":"545","author":"Cheng","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2021.174659_bib11","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1124\/mol.111.073734","article-title":"Long-term alpha1A-adrenergic receptor stimulation improves synaptic plasticity, cognitive function, mood, and longevity","volume":"80","author":"Doze","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174659_bib12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.bcp.2018.01.002","article-title":"The structural determinants of the bitopic binding mode of a negative allosteric modulator of the dopamine D2 receptor","volume":"148","author":"Draper-Joyce","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174659_bib13","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.yjmcc.2004.07.010","article-title":"Genetic enhancement of ventricular contractility protects against pressure-overload-induced cardiac dysfunction","volume":"37","author":"Du","year":"2004","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.ejphar.2021.174659_bib14","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.cardiores.2006.06.015","article-title":"Transgenic alpha1A-adrenergic activation limits post-infarct ventricular remodeling and dysfunction and improves survival","volume":"71","author":"Du","year":"2006","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2021.174659_bib15","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1038\/s41598-018-21100-x","article-title":"Micro-pharmacokinetics: quantifying local drug concentration at live cell membranes","volume":"8","author":"Gherbi","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2021.174659_bib16","first-page":"H1338","article-title":"Overexpression of alpha1B-adrenergic receptor induces left ventricular dysfunction in the absence of hypertrophy","volume":"275","author":"Grupp","year":"1998","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejphar.2021.174659_bib17","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1124\/mol.109.057307","article-title":"alpha1-Adrenergic receptors regulate neurogenesis and gliogenesis","volume":"76","author":"Gupta","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174659_bib18","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.eplepsyres.2008.12.007","article-title":"Alpha-1A adrenergic receptor activation increases inhibitory tone in CA1 hippocampus","volume":"84","author":"Hillman","year":"2009","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejphar.2021.174659_bib19","doi-asserted-by":"crossref","first-page":"17954","DOI":"10.1074\/jbc.M109.041590","article-title":"A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor","volume":"285","author":"Hurst","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2021.174659_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.eururo.2006.06.012","article-title":"The efficacy of drugs for the treatment of LUTS\/BPH, a study in 6 European countries","volume":"51","author":"Hutchison","year":"2007","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2021.174659_bib21","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0735-1097(01)01396-1","article-title":"Regulation of myocardial betaARK1 expression in catecholamine-induced cardiac hypertrophy in transgenic mice overexpressing alpha1B-adrenergic receptors","volume":"38","author":"Iaccarino","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2021.174659_bib22","doi-asserted-by":"crossref","first-page":"18836","DOI":"10.1074\/jbc.M000112200","article-title":"Evidence for a tandem two-site model of ligand binding to muscarinic acetylcholine receptors","volume":"275","author":"Jakubik","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2021.174659_bib23","doi-asserted-by":"crossref","first-page":"40381","DOI":"10.1038\/srep40381","article-title":"Binding of N-methylscopolamine to the extracellular domain of muscarinic acetylcholine receptors","volume":"7","author":"Jakubik","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2021.174659_bib24","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nchembio.1593","article-title":"A new mechanism of allostery in a G protein-coupled receptor dimer","volume":"10","author":"Lane","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejphar.2021.174659_bib25","doi-asserted-by":"crossref","first-page":"H931","DOI":"10.1152\/ajpheart.2001.281.2.H931","article-title":"Cardiac-directed overexpression of wild-type alpha1B-adrenergic receptor induces dilated cardiomyopathy","volume":"281","author":"Lemire","year":"2001","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejphar.2021.174659_bib26","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/pros.2990220404","article-title":"The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle","volume":"22","author":"Lepor","year":"1993","journal-title":"Prostate"},{"key":"10.1016\/j.ejphar.2021.174659_bib27","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/hh1601.095912","article-title":"Targeted alpha(1A)-adrenergic receptor overexpression induces enhanced cardiac contractility but not hypertrophy","volume":"89","author":"Lin","year":"2001","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2021.174659_bib28","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nmeth.2324","article-title":"A pharmacological organization of G protein-coupled receptors","volume":"10","author":"Lin","year":"2013","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ejphar.2021.174659_bib29","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/s41594-018-0067-z","article-title":"Orthosteric and allosteric action of the C5a receptor antagonists","volume":"25","author":"Liu","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejphar.2021.174659_bib30","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1021\/acschemneuro.9b00656","article-title":"Membrane-dependent binding and entry mechanism of dopamine into its receptor","volume":"11","author":"Lolicato","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejphar.2021.174659_bib31","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1021\/acs.jmedchem.7b01844","article-title":"Small molecule allosteric modulators of G-protein-coupled receptors: drug-target interactions","volume":"62","author":"Lu","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2021.174659_bib32","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0223-5234(03)00100-4","article-title":"An overview of inhibitors of Na(+)\/H(+) exchanger","volume":"38","author":"Masereel","year":"2003","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejphar.2021.174659_bib33","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/med.21633","article-title":"Allosteric modulation of G protein-coupled receptors by amiloride and its derivatives. Perspectives for drug discovery?","volume":"40","author":"Massink","year":"2020","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejphar.2021.174659_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.47.120505.105159","article-title":"Allosteric modulation of G protein-coupled receptors","volume":"47","author":"May","year":"2007","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejphar.2021.174659_bib35","doi-asserted-by":"crossref","first-page":"10109","DOI":"10.1073\/pnas.91.21.10109","article-title":"Myocardial expression of a constitutively active alpha 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy","volume":"91","author":"Milano","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2021.174659_bib36","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S1734-1140(13)71509-3","article-title":"alpha1-Adrenergic receptor subtypes in the central nervous system: insights from genetically engineered mouse models","volume":"65","author":"Nalepa","year":"2013","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejphar.2021.174659_bib37","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3109\/10799893.2010.550008","article-title":"Cardiac and neuroprotection regulated by alpha(1)-adrenergic receptor subtypes","volume":"31","author":"Perez","year":"2011","journal-title":"J. Recept. Signal Transduct. Res."},{"key":"10.1016\/j.ejphar.2021.174659_bib38","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1124\/mol.108.048074","article-title":"Binding of orthosteric ligands to the allosteric site of the M(2) muscarinic cholinergic receptor","volume":"74","author":"Redka","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174659_bib39","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.cardiores.2004.10.009","article-title":"alpha1A- but not alpha1B-adrenergic receptors precondition the ischemic heart by a staurosporine-sensitive, chelerythrine-insensitive mechanism","volume":"65","author":"Rorabaugh","year":"2005","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2021.174659_bib40","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1248\/bpb.35.72","article-title":"Tamsulosin potently and selectively antagonizes human recombinant alpha(1A\/1D)-adrenoceptors: slow dissociation from the alpha(1A)-adrenoceptor may account for selectivity for alpha(1A)-adrenoceptor over alpha(1B)-adrenoceptor subtype","volume":"35","author":"Sato","year":"2012","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejphar.2021.174659_bib41","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.drudis.2017.02.002","article-title":"Kinetics for Drug Discovery: an industry-driven effort to target drug residence time","volume":"22","author":"Schuetz","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejphar.2021.174659_bib42","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/84529","article-title":"Overstimulation of the alpha1B-adrenergic receptor causes a \"seizure plus\" syndrome","volume":"7","author":"Seppi","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2021.174659_bib43","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1080\/19336950.2016.1207021","article-title":"5-(N, N-Hexamethylene) amiloride is a GABA-A rho1 receptor positive allosteric modulator","volume":"10","author":"Snell","year":"2016","journal-title":"Channels"},{"key":"10.1016\/j.ejphar.2021.174659_bib44","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1006\/nlme.2000.3965","article-title":"A behavioral study of alpha-1b adrenergic receptor knockout mice: increased reaction to novelty and selectively reduced learning capacities","volume":"75","author":"Spreng","year":"2001","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.ejphar.2021.174659_bib45","doi-asserted-by":"crossref","first-page":"22639","DOI":"10.1038\/srep22639","article-title":"The pathway of ligand entry from the membrane bilayer to a lipid G protein-coupled receptor","volume":"6","author":"Stanley","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2021.174659_bib46","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1016\/S0024-3205(02)02012-X","article-title":"Transgenic studies of alpha(1)-adrenergic receptor subtype function","volume":"71","author":"Tanoue","year":"2002","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2021.174659_bib47","doi-asserted-by":"crossref","first-page":"H1079","DOI":"10.1152\/ajpheart.2000.279.3.H1079","article-title":"Adverse effects of constitutively active alpha(1B)-adrenergic receptors after pressure overload in mouse hearts","volume":"279","author":"Wang","year":"2000","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejphar.2021.174659_bib48","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S0022-3565(24)29473-8","article-title":"Alpha(1) and beta(2) adrenoreceptor agonists inhibit pentylenetetrazole-induced seizures in mice lacking norepinephrine","volume":"298","author":"Weinshenker","year":"2001","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2021.174659_bib49","doi-asserted-by":"crossref","first-page":"7764","DOI":"10.1523\/JNEUROSCI.21-19-07764.2001","article-title":"Genetic comparison of seizure control by norepinephrine and neuropeptide Y","volume":"21","author":"Weinshenker","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2021.174659_bib50","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature14287","article-title":"Two disparate ligand-binding sites in the human P2Y1 receptor","volume":"520","author":"Zhang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2021.174659_bib51","doi-asserted-by":"crossref","first-page":"13738","DOI":"10.1074\/jbc.M008693200","article-title":"Hypotension, autonomic failure, and cardiac hypertrophy in transgenic mice overexpressing the alpha 1B-adrenergic receptor","volume":"276","author":"Zuscik","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2021.174659_bib52","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/82207","article-title":"Overexpression of the alpha1B-adrenergic receptor causes apoptotic neurodegeneration: multiple system atrophy","volume":"6","author":"Zuscik","year":"2000","journal-title":"Nat. Med."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921008153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921008153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:57:46Z","timestamp":1757977066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299921008153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":52,"alternative-id":["S0014299921008153"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174659","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterisation of bis(4-aminoquinoline)s as \u03b11A adrenoceptor allosteric modulators","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174659","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"174659"}}